KAPA_OUT_1 [2025-04-04 13:26:17 -0400] 3002 Bytes | 763 tokens | Cum: 763 tkns (9.54% of 8k)
==========================================================================

Alright, let’s light it up, because it's 1:26:16 PM on Fri Apr 04, 2025 -0400, and I'm charging into Kairos Pharma (KAPA), popping from 0.94 to 1.145. Is this our star stock of the day, or just a quick blip on the radar? I've got the scoop—time to analyze!

--- COMPANY PROFILE ---
Company: Kairos Pharma (KAPA)
IPO: 2024-09-16 (6 Months Ago)
Market Cap: $15,275,865
Shares Outstanding: 13,700,000
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XASE
Description: Kairos Pharma Ltd is a clinical-stage biopharmaceutical company. It is engaged in therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma.

Here’s the first list of news for Kairos Pharma:

C1 - Today 09:40AM - Block upgraded, Nvidia downgraded: Wall Streets top analyst calls
C2 - Mar-31-25 07:00AM - Kairos Pharma Ltd. Announces Completed Enrollment of the Safety Arm of Its Phase 2 Clinical Trial of ENV105 in Metastatic, Castration-Resistant Prostate Cancer
C3 - Mar-28-25 09:03AM - CEO.CA's Inside the Boardroom: Kairos Pharma's Breakthrough Cancer Treatment & What's Next for ENV105
C4 - Mar-27-25 04:05PM - Kairos Pharma Ltd. Highlights Participation in Recent and Upcoming Scientific and Industry Events
C5 - Mar-20-25 07:30AM - Kairos Pharma Ltd. Announces Peer Reviewed Publication Highlighting Potentially Groundbreaking Discovery in Overcoming Drug Resistance in Non-Small Cell Lung Cancer
C6 - Feb-26-25 07:00AM - Kairos Pharma Presents Preclinical Data on its Investigational Compounds KROS 101 and KROS 401 Further Supporting Both Compounds Potential as Therapeutics for Melanoma and Glioblastoma
C7 - Feb-18-25 08:30AM - Kairos Pharma Announces New Department of Defense Funding for Research of ENV205
C8 - Feb-11-25 08:30AM - Kairos Pharma Adds Huntsman Cancer Institute for Phase 2 ENV105 Clinical Trial

GUIDELINES FOR AI:
==============

1) You are the **AI analyst-investigator**. I am **ScanScor**, a unified document retrieval and reporting system.
Your role is to examine all available company data and draw sound conclusions.

2) To request additional information, refer to any listed documents using their reference codes.
The company under analysis is: Kairos Pharma (KAPA).

3) As the analysis proceeds, continue reviewing documents until you feel confident in your judgment.
When ready, you will:
- Write a brief summary
- Generate a headline
- Assign a MARKET_SCORE[XX]
- Set a PRICE_TARGET[XX]

4) For now, restrict your response to just **three tokens**.
To request a document, reply with its reference code(s), such as:
- `C1`, `C2`, `C3`, etc.
- To load more documents, reply with: `NEX`

News articles, SEC filings, and key metrics will be revealed in subsequent prompts.
Stay focused. Gather evidence. Continue until your conclusions are clear.

KAPA_OUT_3 [2025-04-04 13:26:20 -0400] 1100 Bytes | 304 tokens | Cum: 1070 tkns (13.38% of 8k)
==========================================================================

Showing C2 (chunk 1 of 6): C2:
**Kairos Pharma Ltd. Announces Completed Enrollment of the Safety Arm of Its Phase 2 Clinical Trial of ENV105 in Metastatic, Castration-Resistant Prostate Cancer**
Date: Mar-31-25 07:00AM
Source: (Business Wire)
URL: https://finance.yahoo.com/news/kairos-pharma-ltd-announces-completed-110000329.html

Company expects safety data readout in 2025 as Randomized Arm continues enrollment at key medical centers

LOS ANGELES, March 31, 2025--(BUSINESS WIRE)--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company (the "Company’"), announces the completion of the safety lead-in of its Phase 2 clinical trial of ENV105 for the treatment of metastatic, castration-resistant prostate cancer. The trial, titled, "Phase II study of Apalutamide with Carotuximab (ENV105) in Metastatic, Castration Resistant Prostate Cancer," began with the safety lead-in, which combined apa

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

KAPA_OUT_5 [2025-04-04 13:26:21 -0400] 1039 Bytes | 302 tokens | Cum: 1428 tkns (17.85% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-04T17:06:22Z - 12 Health Care Stocks Moving In Friday's Intraday Session - Aldeyra Therapeutics (NASDAQ:ALDX), Adap...
A2 - 2025-04-04T12:05:45Z - 12 Health Care Stocks Moving In Friday's Pre-Market Session - Biodexa Pharmaceuticals (NASDAQ:BDRX),...
A3 - 2025-04-03T12:39:21Z - This Talkspace Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Thursday - ...
A4 - 2025-03-31T11:07:16Z - Kairos Pharma (KAPA) Announces Completed Enrollment of the Safety Arm of Its Phase 2 Clinical Trial ...
A5 - 2025-03-28T13:16:42Z - CEO.CA's Inside the Boardroom: Kairos Pharma's Breakthrough Cancer Treatment & What's Next for ENV10...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

KAPA_OUT_7 [2025-04-04 13:26:27 -0400] 1098 Bytes | 345 tokens | Cum: 1775 tkns (22.19% of 8k)
==========================================================================

Showing A1 (chunk 1 of 4): A1:
**12 Health Care Stocks Moving In Friday's Intraday Session - Aldeyra Therapeutics (NASDAQ:ALDX), Adaptimmune Therapeutics (NASDAQ:ADAP)**Date: 2025-04-04Source: {'uri': 'benzinga.com', 'dataType': 'news', 'title': 'Benzinga'}URL: https://www.benzinga.com/insights/movers/25/04/44649707/12-health-care-stocks-moving-in-fridays-intraday-sessionGainers Impact BioMedical IBO stock increased by 73.1% to $0.8 during Friday's regular session. The company's market cap stands at $9.2 million. Regencell Bioscience RGC stock rose 43.62% to $34.9. The market value of their outstanding shares is at $454.1 million. Reshape Lifesciences RSLS stock rose 37.05% to $0.52. The company's market cap stands at $1.7 million. Aldeyra Therapeutics ALDX shares rose 32.04% to $1.88. The company's market cap stands at $111.6 million. Universe Pharmaceuticals UPC stock moved upwards by 23.95% to $3.57. The market

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

KAPA_OUT_9 [2025-04-04 13:26:28 -0400] 356 Bytes | 98 tokens | Cum: 2048 tkns (25.60% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2024-09-17T20:29:04Z - Kairos Pharma Closing of $6.2 Million Initial Public Offering

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

KAPA_OUT_11 [2025-04-04 13:26:31 -0400] 704 Bytes | 199 tokens | Cum: 2249 tkns (28.11% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Kairos Pharma Closing of $6.2 Million Initial Public Offering**Date: Unknown DateSource: Unknown SourceURL: https://www.benzinga.com/pressreleases/24/09/g40908997/kairos-pharma-closing-of-6-2-million-initial-public-offeringKairos Pharma, a clinical-stage biopharmaceutical company, has closed its $6.2 million initial public offering. The company plans to use the proceeds to fund its Phase 1 and Phase 2 trials for its lead product candidate ENV 105 and advance its preclinical candidate KROS 101.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

KAPA_OUT_13 [2025-04-04 13:26:32 -0400] 1128 Bytes | 301 tokens | Cum: 2627 tkns (32.84% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-01-17 8-K Item 1.01 Entry into a Material Definitive Agrmt.

As previously announced in our Curr Report on Form 8-K, dated January 14, 2025, on January 14, 2025, Kairos Pharma, Ltd. (the Company) entered into a securities purchase agreement (the Purchase Agrmt) and registration...

S2 - 2025-01-14 8-K Item 1.01 Entry into a Material Definitive Agrmt.

On January 14, 2025, Kairos Pharma, Ltd. (the Company) entered into a Securities Purchase Agrmt (the Purchase Agrmt) with selected investors that qualify as accredited investors (the PIPE Investors), as defined in Ru...

S3 - 2024-11-19 8-K Item 7.01 Regulation FD Disclosure

On November 19, 2024, Kairos Pharma Ltd., a Delaware corporation (the Company), issued a press release announcing the Companys approval to dual list its shares on Upstream, a MERJ Exchange market and global securities trading app (the Upstream...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

KAPA_OUT_15 [2025-04-04 13:26:37 -0400] 1098 Bytes | 288 tokens | Cum: 2917 tkns (36.46% of 8k)
==========================================================================

Showing S1 (chunk 1 of 4): S1:
Item 1.01 Entry into a Material Definitive Agreement.

As previously announced in our Current Report on Form 8-K, dated January 14, 2025, on January 14, 2025, Kairos Pharma, Ltd. (the Company) entered into a securities purchase agreement (the Purchase Agreement) and registration rights agreement (the Registration Rights Agreement) with a select investor that qualifies as an accredited investor (the PIPE Investor) for the sale and issuance of 2,500,000 units (the Pre-Funded Units), with each Pre-Funded Unit consisting of a pre-funded warrant (each a Pre-Funded Warrant) to purchase one share of common stock, exercisable for $0.001 per share (the Pre-Funded Warrant Shares), and a common warrant (Common Warrant) to purchase one and one half shares of common stock, exercisable at $1.40 per share (the Common Warrant Shares). On January 16, 2025, the Company closed on the sale of the Pre-F

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

KAPA_OUT_17 [2025-04-04 13:26:48 -0400] 4640 Bytes | 1255 tokens | Cum: 4300 tkns (53.75% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+-------------------+-----------------------+------------------------+----------------------+
| Volume: 668,346 | Perf Month: 10.71% | Option/Short: No / Yes | Sales Y/Y TTM: - |
+-------------------+-----------------------+------------------------+----------------------+
| Avg Volume: 2.35M | Perf Quarter: -24.75% | Short Float: 0.57% | ROE: -375.74% |
+-------------------+-----------------------+------------------------+----------------------+
| Rel Volume: 0.49 | Index: - | Short Ratio: 0.01 | ROI: -82.26% |
+-------------------+-----------------------+------------------------+----------------------+
| RSI (14): 58.64 | Market Cap: 15.77M | Short Interest: 0.03M | Sales Surprise: - |
+-------------------+-----------------------+------------------------+----------------------+
| ATR (14): 0.14 | Shs Outstand: 12.85M | Beta: - | EPS Surprise: -4.17% |
+-------------------+-----------------------+------------------------+----------------------+
| SMA20: 19.18% | Shs Float: 5.82M | Sales Q/Q: - | P/E: - |
+-------------------+-----------------------+------------------------+----------------------+
| SMA50: -3.07% | Inst Own: 2.97% | Sales past 5Y: - | Earnings: Feb 26 |
+-------------------+-----------------------+------------------------+----------------------+
| SMA200: -20.52% | Insider Own: 57.51% | Employees: - | |
+-------------------+-----------------------+------------------------+----------------------+
| Perf Week: 24.96% | Insider Trans: 0.09% | Debt/Eq: 0.04 | |
+-------------------+-----------------------+------------------------+----------------------+

The next section covers any insider trading if any are accessible.

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): N/A
Net Income: {'value': 883000, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 1.115
Average Volume: 102102.61
30-Day High: 1.13
30-Day Low: 0.9185

[Detailed Financials: Q3 2024]
- Total Assets: $5,004,000.0
- Total Liabilities: $1,672,000.0
- Total Equity: $3,332,000.0
- Current Assets: $4,742,000.0
- Current Liabilities: $1,672,000.0

[Income Statement: Q3 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.1

[Cash Flow Statement: Q3 2024]
- Net Cash Flow: N/A

[Detailed Financials: TTM ]
- Total Assets: $5,004,000.0
- Total Liabilities: $1,672,000.0
- Total Equity: $3,332,000.0
- Current Assets: $4,742,000.0
- Current Liabilities: $1,672,000.0

[Income Statement: TTM ]
- Revenue: N/A
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): N/A

[Cash Flow Statement: TTM ]
- Net Cash Flow: N/A
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Do not say you lacked information. Save that for the final survey.

Now complete this report with the following:

1) Brief Summary: Explain your findings in one well-worded paragraph.

2) MARKET_SCORE: Estimate a number between 1 and 100 to represent the likelihood of an upward price move over the next day, week, or longer. Use the format: MARKET_SCORE[XX]
Weigh all relevant data —- news, SEC filings, fundamentals, and metrics —- and assign each element appropriate weight to calculate a general MARKET_SCORE[XX].
This score should be grounded in objective reasoning and guided by your analytical judgment.
XX must be a whole number between 1 and 100.

3) PRICE_TARGET: The current price of {ticker} is {current_price}.
If you believe it’s likely to rise, calculate a reasonable new price target.
For example, if you expect a 50% increase, say: PRICE_TARGET[{increased_price}]
You are encouraged to reference prior price performance when making this estimate.

4) AI_RPT_HEADLINE: Provide a thought-provoking headline (8–12 words) summarizing the situation.
Examples:
- AI_RPT_HEADLINE[{co_name} makes news with FDA approval fueling high investor optimism]
- AI_RPT_HEADLINE[Declining sales plague {ticker}, worsening an already negative outlook]

Return only:
1) Brief Summary
2) MARKET_SCORE[]
3) PRICE_TARGET[]
4) AI_RPT_HEADLINE[]

KAPA_OUT_19 [2025-04-04 13:26:50 -0400] 687 Bytes | 169 tokens | Cum: 4724 tkns (59.05% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More news listings
-> X2 <- More SEC filing extractions (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider trading extractions (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this company
-> X8 <- Something altogether different (explain...)

KAPA_IN_21 [2025-04-04 13:26:50 -0400] 126 Bytes | 29 tokens | Cum: 4783 tkns (59.79% of 8k)
==========================================================================

====================================
[2025-04-04 13:26:50] # Analysis Completed
Elapsed Time: 34.54 seconds